Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Pathway to Cures (P2C) is the venture philanthropy fund of the National Bleeding Disorders Foundation (NBDF), dedicated to accelerating the development of cures for inheritable blood disorders. Operating independently, P2C leverages NBDF's resources and expertise to fill the funding gap in early-stage therapy development. The fund focuses on North America and targets investments in biotech and healthcare sectors.
P2C invests in early-stage companies developing therapies and technologies for inheritable blood and bleeding disorders. Their investment strategy includes a focus on RNA technology, engineered B-cells, and non-invasive medical devices. Typical funding opportunities include pre-seed, seed, and seed+ rounds, aiming to attract additional capital from traditional venture capital and pharmaceutical entities.
P2C's portfolio features investments in innovative areas such as ASO therapeutics for Factor XI deficiency, synthetic fatty acid small molecules for Sickle Cell Disease, and engineered B-cell medicine for Hemophilia B. They also support non-invasive vagus nerve stimulation for Von Willebrand Disease and non-viral mediated genetic medicines for Hemophilia A & B.
Email your pitch deck to info@pathwaytocures.org for consideration.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.